Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells (Q39499064)

12 September 2017

title

Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells (English)

1 reference

12 September 2017

human polyomavirus

1 reference

Biswa Nath Sharma

1 reference

12 September 2017

Ruomei Li

1 reference

12 September 2017

Eva Bernhoff

1 reference

12 September 2017

Tore Jarl Gutteberg

1 reference

12 September 2017

Christine Hanssen Rinaldo

1 reference

12 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21798289

8 December 2024

publication date

21 July 2011

1 reference

full work available at URL

12 September 2017

https://api.elsevier.com/content/article/PII:S0166354211003834?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

https://api.elsevier.com/content/article/PII:S0166354211003834?httpAccept=text/plain

8 December 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

8 December 2024

1 reference

12 September 2017

1 reference

12 September 2017

1 reference

12 September 2017

page(s)

115-123

1 reference

Fleroxacin: the newly introduced once-daily quinoline.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Leflunomide inhibition of BK virus replication in renal tubular epithelial cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco‐2) cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Conformational rearrangements of SV40 large T antigen during early replication events.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Polyomavirus BK infection in blood and marrow transplant recipients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

CMX001 (1- O -Hexadecyloxypropyl-Cidofovir) Inhibits Polyomavirus JC Replication in Human Brain Progenitor-Derived Astrocytes

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

A two fusion partner system for raising antibodies against small immunogens expressed in bacteria

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Treatment of polyomavirus infection in kidney transplant recipients: a systematic review.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Impact of prophylactic administration of ciprofloxacin on BK polyoma virus replication

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Safety profile of the fluoroquinolones: focus on levofloxacin

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Anti-BK virus activity of ciprofloxacin and related antibiotics

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Quantitation of viral DNA in renal allograft tissue from patients with BK virus nephropathy

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Antivirals for the treatment of polyomavirus BK replication

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis

8 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.ANTIVIRAL.2011.07.012

8 December 2024

Identifiers

DOI

1 reference

12 September 2017

1 reference